Overview

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Status:
Completed

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

Summary

Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.

Phase:

Phase 3

Details

Lead Sponsor:

Cosmo Technologies Ltd

Treatments:

Methylene Blue